Leucovorin Statistics in US 2026 | Uses & Facts

Leucovorin in America 2026

Leucovorin — also known as folinic acid and sold under the brand name Wellcovorin — is one of the most clinically significant drugs in the United States pharmaceutical landscape, and in 2025 and 2026, it has become one of the most publicly discussed as well. For decades, leucovorin’s primary role was straightforward: it is a synthetic metabolite of folate (vitamin B9) used in two well-established medical contexts — to reduce the toxic side effects of methotrexate chemotherapy, and as a critical component of colorectal cancer treatment regimens like FOLFOX and FOLFIRI, which together represent the backbone of care for the approximately 152,810 new colorectal cancer cases diagnosed in the United States in 2024. That clinical profile began to shift dramatically in September 2025, when a White House briefing — attended by President Donald Trump, HHS Secretary Robert F. Kennedy Jr., and FDA Commissioner Dr. Marty Makary — promoted leucovorin as a potential treatment for children with autism spectrum disorder (ASD), triggering one of the most dramatic demand-driven prescription surges ever recorded in modern US pharmacology.

What followed was a case study in how public health communications at the highest levels of federal government can reshape clinical practice almost overnight. Within weeks of the September 22, 2025 White House announcement, new leucovorin prescriptions doubled nationally, according to a landmark study published in The Lancet in March 2026 and authored by researchers from Brown University’s School of Public Health and Harvard Medical School. That study, which analyzed data from nearly 300 million patients in a large national electronic medical records database, documented a 71% increase in leucovorin prescriptions for children aged 5 to 17 in the three months following the White House briefing — with prescriptions during the first month running 93% above expected baseline levels. On March 10, 2026 — just two days before the publication of this article — the FDA formally approved leucovorin for a new indication: cerebral folate transport deficiency (CFTD) caused by a mutation in the FOLR1 gene, an ultrarare genetic condition affecting fewer than 1 in 1 million people in the United States. Critically, the agency simultaneously walked back earlier suggestions that leucovorin could broadly benefit the autism population, clarifying that insufficient data existed to establish efficacy for autism beyond this specific, narrowly defined genetic condition.

Interesting Leucovorin Facts in the US 2026

Source: U.S. Food and Drug Administration (FDA); The Lancet (Faust & Barnett, March 2026); Brown University School of Public Health / Harvard Medical School; National Cancer Institute (NCI) SEER Program; American Society of Health-System Pharmacists (ASHP); American Cancer Society

The sheer breadth of the leucovorin data landscape in 2026 reflects how completely this drug’s public profile has been transformed in a matter of months. A medication that oncologists and hematologists had been quietly prescribing within established chemotherapy regimens for decades suddenly found itself at the intersection of federal health policy, autism advocacy, social media virality, and drug supply chain vulnerability — all at once. The 71% prescription surge among pediatric patients is not a rounding error; it is a statistically robust signal drawn from one of the largest patient databases in the world, and it left pharmacies across the country scrambling to fill prescriptions that manufacturers simply were not prepared to supply at that volume. The ReligenDX testing company’s data — processing 7 times more folate receptor autoantibody tests at peak demand — independently corroborates the scale of the surge, coming from an entirely separate part of the clinical pathway.

The FDA’s March 10, 2026 approval decision is equally revealing in what it did and did not do. Approving leucovorin for CFTD/FOLR1 was a scientifically defensible step supported by case-level evidence from 46 patients across 15 years of published literature — 24 of 27 oral leucovorin patients in that dataset showed documented clinical improvement in neurological symptoms. But the simultaneous refusal to extend approval to autism more broadly — a population of millions versus the fewer than 50 CFTD cases ever identified worldwide — is a clear statement from FDA that the clinical evidence base simply does not support the broader claims made at the September 2025 White House briefing. For the millions of American families navigating autism treatment decisions, the message from federal regulators as of March 2026 is unambiguous: the evidentiary bar for leucovorin and autism has not yet been cleared.

Uses of Leucovorin in the US 2026

Source: U.S. Food and Drug Administration (FDA) Official Prescribing Information (accessdata.fda.gov); FDA March 10, 2026 approval announcement; NIH/HHS Clinical Guidelines — Adult and Adolescent Opportunistic Infections (clinicalinfo.hiv.gov); NCBI StatPearls — Folinic Acid (updated February 28, 2024); NCBI StatPearls — Leucovorin (updated July 2023); Drugs.com Leucovorin Dosage Guide (updated August 26, 2025); NCI Cancer.gov FOLFOX drug entry

The breadth of leucovorin’s clinical applications in the US in 2026 reflects a drug with a genuinely unusual pharmacological profile. Its core biochemical property — the ability to act as a reduced, active form of folate that bypasses the dihydrofolate reductase (DHFR) enzyme entirely — makes it useful in two seemingly opposite directions at the same time. On one hand, it rescues healthy cells from the folate-blocking effects of methotrexate and other folic acid antagonists — acting as an antidote by replenishing folate pathways that MTX has deliberately shut down. On the other hand, in colorectal cancer chemotherapy, it does the opposite: it potentiates and enhances the killing power of 5-fluorouracil (5-FU) by stabilizing the bond between 5-FU’s active metabolite and the enzyme thymidylate synthase, making cancer cells more susceptible to the drug’s DNA-disrupting action. That dual role — as both rescue agent and chemotherapy amplifier — is what makes leucovorin irreplaceable in modern oncology. No other single drug in routine clinical use performs both functions simultaneously within established, multi-decade standard-of-care protocols.

The off-label use landscape adds several additional layers of clinical complexity. In HIV/AIDS medicine, leucovorin has long been embedded in alternative prophylaxis regimens for both Pneumocystis jirovecii pneumonia (PCP) and toxoplasmosis — specifically in patients who cannot tolerate the first-line agent trimethoprim-sulfamethoxazole. These uses are supported at the NIH Evidence Level BI, meaning they are backed by at least one well-designed clinical trial or strong observational evidence, and they are formally incorporated into the US government’s own HIV clinical practice guidelines published by clinicalinfo.hiv.gov. One critical safety caveat in this context is well-documented: leucovorin must not be co-administered with TMP-SMX during active PCP treatment, as the combination can antagonize TMP-SMX’s action and increase the risk of therapeutic failure and mortality — a counter-intuitive interaction that clinicians must navigate with care. At the far end of the off-label spectrum sits the 2025–2026 autism prescribing surge, where leucovorin’s use has expanded dramatically into a patient population for which the FDA has explicitly found the evidence insufficient — a disconnect between federal health communications, clinical evidence standards, and real-world prescribing behavior that continues to define the leucovorin story in America in 2026.

Leucovorin Prescription Surge Statistics in the US 2026

Source: The Lancet (Faust JS, Barnett ML, “Changes in paracetamol and leucovorin use after a White House briefing,” March 2026); Brown University School of Public Health press release, March 5, 2026

The prescription surge data published in The Lancet in March 2026 stands as one of the most precisely documented examples of federal health communications directly reshaping clinical practice in US medical history. The research methodology was rigorous: the investigators used a national electronic medical records database covering nearly 300 million patients and controlled for pre-existing trends by examining comparison medications that were not mentioned in the White House briefing. The finding that no similar changes appeared in the comparison drugs — but did appear in both leucovorin and acetaminophen (which was negatively mentioned at the same briefing) — establishes a compelling causal link between the presidential announcement and the nationwide shift in prescribing behavior. This is not background noise; it is a clinically significant, statistically verified signal.

What the data also makes clear is that 72% of the new pediatric leucovorin prescriptions targeted children with autism diagnoses — a group representing just 4% of the pediatric population in the dataset. That ratio is extraordinary. It means the surge was not broadly distributed across pediatric patients with various folate-related conditions; it was almost entirely channeled toward the exact population that the White House briefing had discussed. Prescriptions remained elevated well into December 2025, suggesting that the initial spike was not just a brief flush of curiosity-driven prescribing but represented a sustained shift in clinical behavior that continued for months after the announcement. The gradual pre-briefing increase detected between February and November 2025 — linked to earlier media coverage — adds further nuance, showing that public interest in leucovorin for autism was already building before the White House event dramatically accelerated it.

Leucovorin FDA Approval and Clinical Authorization in the US 2026

Source: U.S. Food and Drug Administration (FDA), March 10, 2026 approval announcement; American Academy of Pediatrics; Child Neurology Society; Neurology Advisor (March 11, 2026)

The FDA’s March 10, 2026 approval of leucovorin for CFTD/FOLR1 is significant precisely because of how narrow it is. The agency approved the drug for a condition with fewer than 50 confirmed cases in the entire world — a population so small that the approval was based not on a traditional randomized controlled trial but on a systematic literature review of case reports spanning 15 years. The 89% neurological response rate (24 of 27 patients) in that case-report dataset is clinically compelling for the specific FOLR1 mutation — a condition where a genetic defect prevents folate from being transported into the brain via the primary receptor, causing documented movement disorders, seizures, and neurological regression. In that context, leucovorin’s value is clear: it enters the brain through an alternative pathway, effectively bypassing the dysfunctional transporter and restoring brain folate levels.

What the approval does not do — and what the FDA explicitly stated it was refusing to do — is validate the broader claim made at the September 2025 White House briefing that 20% to 50% of children with autism might benefit from leucovorin. The FDA’s decision to simultaneously publish approval for the ultrarare FOLR1 condition while issuing a clear refusal on the autism-specific indication is a textbook example of the agency trying to recalibrate expectations that federal officials had dramatically overextended. The additional disclosure that the largest randomized, double-blind, placebo-controlled trial supporting leucovorin’s use in autism was retracted in early 2026 after data errors were identified further undermines the evidentiary case. The American Academy of Pediatrics and the Child Neurology Society have both issued guidance advising against routine use — leaving clinicians in 2026 navigating between elevated parental demand and a lack of supporting professional society endorsement.

Leucovorin Drug Shortage Statistics in the US 2026

Source: American Society of Health-System Pharmacists (ASHP) Drug Shortage Bulletins (Leucovorin Calcium Tablets and Injection); FDA Drug Shortage Database; PMC analysis “Key Drivers and Mitigation Strategies of Oncology Drug Shortages 2023 to 2025” (2025)

The leucovorin shortage story in 2025 and 2026 is a perfect, if painful, illustration of what public health economists call a demand-side shortage. The drug did not suddenly become harder to manufacture in the fall of 2025. Manufacturers had not changed their production processes. What changed was that a single White House press conference sent new pediatric prescriptions doubling overnight, overwhelming pharmacy shelf stocks that had been calibrated for the drug’s historical demand profile in chemotherapy and metabolic medicine — not for a nationwide surge in autism-related off-label use. Most leucovorin tablet manufacturers had their supplies on allocation or backorder within weeks. The FDA took the rare step of issuing a “Dear Provider” letter in December 2025 to announce it was authorizing emergency imports from Pfizer’s Canadian supply, manufactured by Farmasierra in Madrid, Spain — an intervention reserved for situations where domestic supply genuinely cannot meet patient need, even if the FDA stopped short of formally listing leucovorin tablets as being in shortage on its official shortage database.

The deeper structural problem, however, predates the 2025 surge by more than a decade. The PMC analysis of oncology drug shortages — published in 2025 — found that leucovorin calcium holds the record for the longest-running shortage among oncology drugs tracked in the FDA Drug Shortage Database, spanning over 13 years. Nine separate manufacturers have exited the leucovorin market over that period. This persistent market fragility stems from the drug’s generic status and the economic reality that low-profit-margin generic drugs offer little financial incentive for manufacturers to invest in resilient, high-capacity production infrastructure. The 2025–2026 demand surge simply exposed and amplified a vulnerability that cancer care teams and pharmacists had been quietly navigating for years — a vulnerability that, left unaddressed, creates real risks for the colorectal cancer patients who depend on leucovorin-containing regimens as part of their standard of care.

Leucovorin in Colorectal Cancer Treatment in the US 2026

Source: National Cancer Institute (NCI) SEER Cancer Stat Facts; American Cancer Society; New England Journal of Medicine (FOLFOX adjuvant trial); NCI Cancer.gov FOLFOX drug entry; ScienceDirect CRC incidence study (2025)

Leucovorin’s role in colorectal cancer treatment is foundational in a way that is easy to overlook amid the 2025–2026 autism controversy. With 152,810 new colorectal cancer cases diagnosed in 2024, and over 1.39 million Americans currently living with CRC, the number of patients whose treatment depends on leucovorin-containing regimens is orders of magnitude larger than either the autism population using it off-label or the tiny number of FOLR1-CFTD patients for whom it is now formally approved. FOLFOX — which stands for folinic acid (leucovorin), fluorouracil, and oxaliplatin — is the dominant first-line and adjuvant chemotherapy regimen for stage III and metastatic colon cancer in the United States. The improvement it delivers is not marginal: a 53% objective response rate compared to 22% for 5-FU/leucovorin alone in advanced colon cancer, and a 3-year disease-free survival rate of 78.2% vs. 72.9% in the landmark NEJM adjuvant trial. Leucovorin’s biochemical role — potentiating the cytotoxic action of 5-fluorouracil (5-FU) by stabilizing the drug’s binding to its molecular target — is what makes those outcomes possible.

The NCI SEER data showing CRC incidence declining from 136.9 to 115.9 per 100,000 among eligible adults between 2021 and 2024 represents genuine progress in early detection and prevention. But with 53,010 Americans still expected to die from colorectal cancer in 2024, and CRC holding its rank as the second leading cause of cancer death in the United States, the treatment landscape that depends on reliable leucovorin supply remains critically important. When leucovorin goes on backorder — as it repeatedly has over its 13-plus-year shortage history — it is not just an inconvenience for autism families seeking an off-label prescription. It is a direct threat to cancer patients mid-treatment, and oncology pharmacists have developed contingency protocols and dose-sparing regimens specifically because they cannot always guarantee drug availability. The 2025–2026 demand surge from off-label autism prescribing adds yet another layer of complexity to an already chronically fragile supply chain.

Leucovorin Off-Label Use, Autism, and Clinical Evidence in the US 2026

Source: U.S. Food and Drug Administration (FDA); American Academy of Pediatrics (AAP); Child Neurology Society; CDC Autism and Developmental Disabilities Monitoring Network; CNN (March 5 and March 10, 2026); KESQ / ABC News reporting (March 11, 2026)

The off-label use landscape for leucovorin in autism as of 2026 is one of the most contested areas in US pediatric pharmacology, and the data tells a story of substantial clinical caution sitting uneasily alongside an extraordinary surge in real-world prescribing. The estimated 20–30% off-label prescription rate across all US prescriptions illustrates that off-label prescribing is routine and legally permissible — but medical consensus generally holds that off-label use should be supported by meaningful published evidence, something the autism-leucovorin literature has not yet convincingly established at scale. The retraction in early 2026 of the largest autism-leucovorin randomized controlled trial due to data errors left the evidentiary case weaker than it had appeared even months before, and the FDA’s inability to identify sufficient evidence even after a formal review — the explicit purpose of the September 2025 announcement — is as close to a definitive federal statement on the current evidence base as is likely to emerge in the near term.

The practical consequences for families are severe and are backed by documented data. Test costs of nearly $300 per folate receptor autoantibody test, paid entirely out of pocket, represent a meaningful financial barrier — particularly given that the broader research community does not endorse this test as accurate or reliable. The surge in test volume to 7 times normal monthly levels at ReligenDX demonstrates that the White House announcement created a new commercial ecosystem almost overnight, one that Dr. Sarah Mohiuddin of Michigan Medicine and others have warned contains “bad-faith players” willing to exploit families’ desire for any effective autism treatment. The sustainability of this ecosystem is also uncertain: ReligenDX’s sustained volume at 6 times pre-surge levels suggests that even after the FDA’s March 2026 clarification, significant demand for testing — and by extension, for leucovorin prescriptions — will persist. That sustained demand creates ongoing pressure on a drug supply chain that, as the 13-year ASHP shortage history makes clear, was never designed to accommodate this level of usage.

Leucovorin Supply Chain and Manufacturer Data in the US 2026

Source: American Society of Health-System Pharmacists (ASHP) Drug Shortage Bulletins; FDA Drug Shortages Database; U.S. Department of Health and Human Services; PMC “Key Drivers and Mitigation Strategies of Oncology Drug Shortages 2023 to 2025” (2025); Gateway Health Partners Drug Shortage Update (June 2025)

The leucovorin supply chain crisis of 2025–2026 sits inside a much larger, chronic problem with pharmaceutical supply resilience in the United States. With 270 active drug shortages tracked by the ASHP as of April 2025 — and more than 40% of those dating to 2022 or earlier — the US healthcare system is not experiencing a temporary glitch but a structural failure in how generic drug markets are incentivized and maintained. The HHS estimate that each shortage affects approximately 500,000 people, with over 30% of those between ages 65 and 85, illustrates the direct patient safety stakes of market concentration and manufacturing fragility. The nine manufacturers who have exited the leucovorin calcium market did not do so out of malice; they exited because the economics of a generic folate-based drug with low margins, complex manufacturing requirements, and regulatory compliance costs made continued production commercially unviable. That rational market behavior produces irrational outcomes for patients.

What the 2025 demand surge added to this pre-existing fragility was a sudden, politically-driven, unpredictable spike in demand that no supply chain model had factored into its planning. Emergency importation from Canada and Spain, allocation rationing by multiple manufacturers, and ASHP shortage bulletins updated as recently as February 17, 2026 are all symptoms of a system under acute stress on top of chronic stress. The $216 million annual cost estimate from the ASHP Drug Shortages Summit for managing drug shortages system-wide understates the full impact: it does not capture the cost of delayed cancer treatment, the cost borne by families who pay out of pocket for unproven tests and imported supplements when prescriptions cannot be filled, or the cost of the additional clinical labor required when pharmacists must identify therapeutic alternatives and manage dose-sparing regimens for their oncology patients. In the leucovorin context specifically, those costs are distributed across one of the most treatment-intensive disease categories in American medicine.